BR112022012281A2 - Combinações - Google Patents
CombinaçõesInfo
- Publication number
- BR112022012281A2 BR112022012281A2 BR112022012281A BR112022012281A BR112022012281A2 BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2 BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A BR112022012281 A BR 112022012281A BR 112022012281 A2 BR112022012281 A2 BR 112022012281A2
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- disease
- compounds
- condition
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952039P | 2019-12-20 | 2019-12-20 | |
| PCT/US2020/065409 WO2021127044A1 (en) | 2019-12-20 | 2020-12-16 | Combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012281A2 true BR112022012281A2 (pt) | 2022-08-30 |
Family
ID=76478095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012281A BR112022012281A2 (pt) | 2019-12-20 | 2020-12-16 | Combinações |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230008362A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069235A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7631348B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220119442A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115427042A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020407070A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022012281A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3165472A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294080A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007626A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202132299A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021127044A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018286A2 (pt) | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| WO2021097139A1 (en) | 2019-11-15 | 2021-05-20 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| KR20230038523A (ko) | 2020-07-09 | 2023-03-20 | 리커리엄 아이피 홀딩스, 엘엘씨 | Wee1 억제제의 염 및 형태 |
| WO2023083194A1 (zh) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1蛋白激酶降解剂及其用途 |
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015183776A1 (en) | 2014-05-29 | 2015-12-03 | Merck Sharp & Dohme Corp. | Methods for treating cancer with a wee1 inhibitor |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| BR112020018286A2 (pt) | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
-
2020
- 2020-12-16 CA CA3165472A patent/CA3165472A1/en active Pending
- 2020-12-16 KR KR1020227025073A patent/KR20220119442A/ko not_active Ceased
- 2020-12-16 JP JP2022538220A patent/JP7631348B2/ja active Active
- 2020-12-16 IL IL294080A patent/IL294080A/en unknown
- 2020-12-16 CN CN202080095235.7A patent/CN115427042A/zh active Pending
- 2020-12-16 WO PCT/US2020/065409 patent/WO2021127044A1/en not_active Ceased
- 2020-12-16 AU AU2020407070A patent/AU2020407070A1/en not_active Abandoned
- 2020-12-16 BR BR112022012281A patent/BR112022012281A2/pt unknown
- 2020-12-16 US US17/757,493 patent/US20230008362A1/en not_active Abandoned
- 2020-12-16 MX MX2022007626A patent/MX2022007626A/es unknown
- 2020-12-16 EP EP20902208.6A patent/EP4069235A4/en active Pending
- 2020-12-18 TW TW109145139A patent/TW202132299A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL294080A (en) | 2022-08-01 |
| EP4069235A4 (en) | 2024-01-10 |
| WO2021127044A1 (en) | 2021-06-24 |
| EP4069235A1 (en) | 2022-10-12 |
| MX2022007626A (es) | 2022-09-23 |
| CN115427042A (zh) | 2022-12-02 |
| KR20220119442A (ko) | 2022-08-29 |
| AU2020407070A1 (en) | 2022-07-14 |
| JP7631348B2 (ja) | 2025-02-18 |
| US20230008362A1 (en) | 2023-01-12 |
| CA3165472A1 (en) | 2021-06-24 |
| JP2023508328A (ja) | 2023-03-02 |
| TW202132299A (zh) | 2021-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012280A2 (pt) | Combinações | |
| BR112022012283A2 (pt) | Combinações | |
| BR112022012278A2 (pt) | Combinações | |
| BR112022012266A2 (pt) | Combinações | |
| BR112022023254A2 (pt) | Monoterapias e terapias de combinação | |
| PT3883579T (pt) | Terapia de combinação incluindo um inibidor de kras-g12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| BR112018074621A2 (pt) | derivados de pirazolopirimidina como inibidores de quinase | |
| BR112018000808A2 (pt) | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase | |
| BR112019007144A2 (pt) | compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase | |
| CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MX2022007626A (es) | Combinaciones. | |
| WO2015184145A8 (en) | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| BR112016030541A2 (pt) | métodos para o tratamento de infecções fúngicas | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX382765B (es) | Tratamiento para la colangitis biliar primaria. | |
| BR112017013982A2 (pt) | fármaco de combinação | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2020012253A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona para el tratamiento del carcinoma quistico adenoide. | |
| BR112022009066A2 (pt) | Ezetimiba para uso em tratamento de câncer | |
| BR112022009035A2 (pt) | Fármaco de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |